Contact Us
Australian company Recce Pharmaceuticals (ASX: RCE) is advancing a synthetic polymer antibiotic designed with optimum properties that exhibits high potency against a broad range of…
READ MORE
DURECT Corporation is advancing an epigenetic regulator program aimed at developing products to treat acute AH and nonalcoholic steatohepatitis (NASH), a type of nonalcoholic fatty…
READ MORE
The critical difference is that older patients and those who are immune-compromised tend to lack a robust T-cell response, which Heat Biologics believes is important…
READ MORE
9 Meters Biopharma is focused on rare gastrointestinal conditions. It is advancing an experimental therapy for short bowel syndrome. We spoke to John Temperato, president…
Listen here
Not long ago, someone asked Lawrence Blatt, Ph.D., the probability that one of his company’s drugs would be successful. “I don’t want to think about…
READ MORE
Chiasma’s Mycapssa (octreotide) has become the first FDA-approved oral therapy to treat acromegaly, a rare disorder in which overproduction of human growth hormone leads to…
READ MORE
Huntington’s disease is a rare and fatal neurodegenerative condition that is without any disease-modifying therapies today. Vaccinex is developing an experimental therapy designed to treat…
Listen here
Dr. Soon-Shiong tells PEOPLE he’s working to create a more universal cancer treatment by rethinking how we use radiation to target cancer cells – and…
READ MORE
This precise approach “makes it possible to make drugs that only act on the cell type you care about,” reducing the unwanted side effects that…
READ MORE
Dr. Jonathan Javitt, the CEO of NeuroRx, said, “We’re talking to people who have critical COVID-19, with respiratory failure. That is people whose lungs have…
READ MORE
“It’s a chronic neurodegenerative process. Chronic just means it goes on very slowly over a long period of time,” said Friedlander, of NeuBase Therapeutics. Holder’s…
READ MORE
Redhill Biopharma Ltd.’s chief operating officer, Gilead Raday, told BioWorld that the firm will build on positive results in severe COVID-19 patients with oral opaganib, a first-in-class sphingosine…
READ MORE
9 Meters Biopharma’s program for celiac disease is among the most clinically advanced programs in development. With phase III trials underway and Fast Track designation…
READ MORE
David Edward Gilham of The University of Manchester discusses single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple…
View clip
It’s early days for Cue Biopharma’s CUE-101, the lead candidate in its IL-2-based CUE-100 Series. In pre-clinical studies, CUE-101 has demonstrated selective binding and preferential…
READ MORE
Despite being most at risk from Covid-19, older people and those with compromised immune systems are unlikely to reap much benefit from Covid-19 vaccines, which…
READ MORE
Moira speaks with Yochi Slonim, CEO of Anima Biotech, talks about the path from your DNA to producing proteins, and the potential for new drugs.
Listen here
Cidara Therapeutics (NASDAQ:CDTX) is developing what may be the first antifungal to be approved in 15 years for both the treatment and prevention of invasive fungal…
READ MORE
When Karen Jackson founded Sisters Network INC. in 1994, a national African American breast cancer survivorship organization, she was optimistic to the point of wearing…
READ MORE
Dr. Patrick Soon-Shiong is a physician, surgeon, researcher, philanthropist, and owner of the LA Times. From 1997–2010, he served as Founder, Chairman and CEO of American Pharmaceutical Partners…
READ MORE
Efficacy, safety, and convenience are hard-to-achieve attributes of cancer therapies, despite the best marketing engines in biopharma. Acepodia—a clinical-stage biotech focused on developing novel, targeted, allogeneic-cell…
READ MORE
Harry M. Reid has a message for these incredibly bleak times: Keep fighting. Last summer the former Senate majority leader hid from the obvious fact…
READ MORE
The scientist whose unorthodox approach helped former Senate Majority Leader Harry Reid beat pancreatic cancer is turning his attention toward fighting coronavirus. Dr. Patrick Soon-Shiong, who said his company ImmunityBio is working…
READ MORE
With deep roots in diabetes, this small company is pushing forward with a trial against a rare diosease known as congenital hyperinsulinism.
READ MORE
Dr. Rebecca Kusko, Chief Strategy Officer at Immuneering Corp., has carved out a purposeful, yet unorthodox, path to the C-suite as well as serving as…
Listen here
Dr. Laurence Cooper, CEO, Ziopharm Oncology points to earlier work in immunotherapy to explain the advances in cancer treatment that revolve around the genetic engineering of…
Listen here
Mark Revord will never know for sure whether an experimental drug, known at the time as CM4620-IE, saved him from having a breathing tube inserted…
READ MORE
Fauci is “cautiously optimistic” that with multiple vaccine candidates being developed using different platforms, we’ll eventually have an effective COVID-19 vaccine. However, Dr. Patrick Soon-Shiong, CEO…
READ MORE
Non-invasive imaging has played an increasing role in drug discovery and development processes. Nikki Withers spoke with Yochi Slonim, who discusses a novel technology that…
READ MORE
CalciMedica Inc. revealed that, in combination with low-flow oxygen therapy, Auxora reduced the proportion of patients put on ventilators by over 50 percent compared to the…
READ MORE
The era of COVID-19 has brought on some exciting developments with the types of biopharmaceutical enterprises that are developing therapies and vaccines to treat the…
READ MORE
Nonalcoholic steatohepatitis is a severe form of fatty liver disease that affects 3% to 5% of the population in the United States and currently no…
READ MORE
Vaccinex’s Phase 2 SIGNAL study, evaluating the investigational antibody pepinemab (VX15/2503) in Huntington’s disease patients with late prodromal and early disease, is ongoing and has tested pepinemab in…
READ MORE
Australian drug developer Recce Pharmaceuticals has announced new data showing significant in-vivo antibacterial activity in mice treated with its lead compound RECCE 327 against Neisseria gonorrhoeae, the second most common…
READ MORE
Best Use of Social Media – Bronze: Using the Power of Social Media to Engage with Target Audiences in a Crowded Disease Space by LifeSci Communications Best Use…
READ MORE
Ben Zeskind launched his biotech, Immuneering, in the throes of the Great Recession. The company earned a $20 million series A round to fund the…
Listen here
“Seeing a group of people become a team and achieving more than they thought was possible inspires me” – Anne Whitaker, CEO, Aerami Therapeutics
READ MORE
The race for a COVID-19 vaccine has a dark horse entrant. Billionaire scientist and businessman Patrick Soon-Shiong announced in a 27 May investor call and…
READ MORE
Molecular diagnostics developer OncoCyte said it will step up its pursuit of coverage by private insurers for its DetermaRx™ non-small cell lung cancer (NSCLC) test,…
READ MORE
Radiation, chemotherapy and surgery don’t cut it against glioblastoma, an aggressive type of brain cancer that often recurs with a vengeance. Ziopharm is working on…
READ MORE
Work is already underway at Valneva’s plant in Livingston on the unique Covid-19 inactivated vaccine.
READ MORE
Filippo Petti, Chief Executive Officer at Celyad, delves into the disruptive potential of CAR T therapies in treating cancer, and explores the challenges that have…
READ MORE
Significant efforts are underway to develop a vaccine against SARS-CoV-2, the virus that has caused the COVID-19 global pandemic. A critical factor of consideration is the potential impact…
READ MORE
As the biotech industry flourishes and therapies become more targeted and personalized, the need for drug developers to interact with patients is increasing as well.…
READ MORE
Jeff Stein, President and CEO, Cidara Therapeutics talks about their antifungal platform rezafungin now in Phase 3 clinical development to address the needs of the…
Listen here
David Hochman, founder and CEO of Orchestra BioMed, shares how the company’s risk-reward sharing business model has helped it stay afloat during the coronavirus pandemic.
READ MORE
Human immunodeficiency virus (HIV) management has come a long way, now making it possible for people with HIV to live longer, healthier lives. Antiretroviral therapy…
READ MORE
Huntington’s disease (HD), also known as Huntington’s chorea, is an inherited genetic disorder that kills brain cells. The Huntington Disease Society of America describes the disease as “a fatal genetic…
READ MORE
Fountain Therapeutics Inc., a California company working to create treatments for age-related diseases, said Khosla Ventures has led a $6 million series A-1 financing of…
READ MORE
“Significant investment, in both time and money, is needed to advance a vaccine candidate to market,” Thomas Lingelbach, CEO of French vaccine developer Valneva, told me. “In…
READ MORE
During the ongoing Covid-19 pandemic, the FDA has continued in its normal role of approving safe and effective drugs. But how do pharma companies go…
READ MORE
Colin talks with Dr. Patrick Soon-Shiong who is not only a Doctor helping to fight Covid-19 but also owns the LA Times and is a…
Listen here
Motus GI has receiving a new United States Patent for the sensing technology and suction control on its Pure-Vu System, a device that fits onto…
READ MORE
Bill Gates and GV have joined in a $45million Series B funding round for Cerevance, the pharmaceutical company with a Cambridge Science Park base. The…
READ MORE
When the coronavirus pandemic shook up Ansun Biopharma Inc.’s clinical-trial plans, company leaders knew they had to change course. San Diego-based Ansun, which has raised…
READ MORE
A specialty vaccine company is seeking grant funding to ramp up production of a potential inoculation against Covid-19 from its Scottish laboratory. French-headquartered Valneva is…
READ MORE
Back injuries are no joke. Even minor muscle strains can inhibit activities for some time. More serious injuries create greater challenges and often require more…
READ MORE
After presenting initial data from Cohorts 1 and 2 of the phase 1 OPTIC trial in 2019, Cohort 3 results announced by Adverum Biotechnologies are…
READ MORE
San Diego-based Ansun Biopharma used its influenza research data to dive into attempts to develop a treatment for COVID-19 using an investigational nebulized enzyme asset…
READ MORE
Use of the hepatocyte growth factor mimetic ANG-3777 showed long-term improvement in kidney function in patients who underwent transplantation but had signs of possible kidney…
READ MORE
Motus GI secured a U.S. patent for its Pure-Vu System’s sensing technology and suction control features. Three quick points: 1. Motus GI’s flagship Pure-Vu System can…
READ MORE
Maurice Zauderer, Ph.D. has served as Vaccinex’s President and Chief Executive Officer and a member of the board of directors since the company’s inception in…
Listen here
Lawrence Blatt, Ph.D., cofounder and CEO of Aligos Therapeutics, a San Francisco-based biotech discovering and developing curative treatments for hepatologic diseases and viral infections, will…
READ MORE
BioMarin (NASDAQ: BMRN) of San Rafael paired with one-year-old Swiss company DiNAQOR AG to develop gene therapies to treat rare genetic heart diseases and Adverum…
READ MORE
David Johnson of GigaGen discusses how recombinant forms of intravenous immunoglobulins (IVIG) could overtake current IVIG therapies and be used in the treatment of COVID-19.…
READ MORE
A group of US academic researchers has sparked a nationwide effort to encourage people who have recovered from COVID-19 to donate plasma, which will be used to…
READ MORE
Introducing 9 Meters Biopharma, the new company birthed from the merger of Raleigh-based Innovate Biopharmaceuticals, a clinical stage biotechnology company focused on developing novel therapeutics for autoimmune…
READ MORE
Producing so many doses will require creating new facilities or commandeering those used for other vaccines. Critics of RNA and DNA vaccines point to the…
READ MORE
It’s early, not even 7 a.m., in fact, and the above statement is prefaced with an apology for interrupting the free-flowing dialogue taking place between…
READ MORE
Synaptive Medical received an FDA clearance for its slightly miniaturized and more-manageable MRI system, the second such device to receive the agency’s green light in…
READ MORE
With the scale of the COVID-19 pandemic still growing, many pharmaceutical companies are adapting their current R&D programmes to develop therapeutics or vaccines to help…
READ MORE
In an interview with CancerNetwork®, Henry Adewoye, MD, chief medical officer at Compugen, discussed the study of COM701, which was presented at the American Association for…
READ MORE
Shares in Valneva SE rose by as much as 32% during early trading April 30 on news that Pfizer Inc. is paying $130 million up front to in-license its…
READ MORE
Positive topline data from the phase 3 REST-ON trial evaluating FT218 (Avadel), an investigational, once-nightly formulation of sodium oxybate, showed that the treatment led to…
READ MORE
Another company focused on severe respiratory complications of COVID-19 is La Jolla, Calif.-based Calcimedica Inc., which started a phase IIa study with its small-molecule calcium release-activated…
READ MORE
A cell-targeting sequencing method developed at Rockefeller University is being used to find drug targets for neurological conditions such as Parkinson’s and Alzheimer’s diseases. Nuclear…
READ MORE
A new type of checkpoint inhibitor from an Israeli biotech company called Compugen is showing early signs of halting tumor growth in patients with advanced…
READ MORE
Immunomedics (IMMU) isn’t concerned the coronavirus pandemic could slow its launch of a new breast cancer treatment, an executive said Thursday, as IMMU stock rocketed on…
READ MORE
Despite oncology being a focus of pharmaceutical R&D for decades, some cancers remain difficult to treat. Drug Target Review’s Hannah Balfour spoke with Hans Klingemann, MD, PhD,…
READ MORE
Cue Biopharma forged a clinical collaboration with Merck to combine its lead candidate CUE-101 with Merck‘s Keytruda as a first-line treatment for HPV+ recurrent/metastatic head and neck cancer.
READ MORE
For high-risk seniors changing how they connect is a must during Coronavirus, and searching for a treatment.
View clip
After outshining the standard of care for yeast infections in a midstage trial, Scynexis’ broad-spectrum antifungal has delivered again. The drug beat placebo at clearing…
READ MORE
GV, Bill Gates and Foresight Capital joined three existing investors in Cerevance’s recent Series B round, which closed with $45m raised. The ability of this…
READ MORE
How Redhill Biopharma is fighting COVID-19
View clip
The question James E. Brown, President & CEO, DURECT asked of CDMOs when he founded the company in 1998 remains perfectly operational. “‘Who are they?’ is…
READ MORE
San Diego biotech company CalciMedica has partnered with two Midwestern hospitals to test a drug designed to help COVID-19 patients who are battling severe pneumonia.
READ MORE
Biotechnology startup Cerevance Inc. has secured $45 million to hunt for treatments for neurological diseases by studying samples of brain tissue gathered from deceased donors…
READ MORE
At GigaGen, a San Francisco-based biotech startup founded by Stanford University professor Dr. Everett Meyer, scientists are identifying the right antibodies from recovered COVID-19 patients and…
READ MORE
Four months after inking its first Big Pharma partnership, Cerevance is topping up its coffers with a $45 million raise. The proceeds will push the company’s…
READ MORE
Research is critical during this pandemic. With so much unknown about the coronavirus, doctors and scientists are exploring new methods to finding a treatment. A…
READ MORE
HealthPartners is now testing a drug which could treat severe COVID-19 pneumonia patients. The drug – called CM4620-IE – received fast-track approval from the FDA…
READ MORE
Scientists at Immunomedics have similarly loaded their ADC IMMU-132 (sacituzumab govitecan) with about eight SN-38 molecules in hopes of killing tumor cells via the bystander…
READ MORE
As the number of COVID-19 cases rises, so does the demand for critical medical supplies, leading governments and companies to ramp up the production of…
READ MORE
“We need to have a more innovative approach to neuroscience; the pharmaceutical industry has been fixated too long on a handful of targets for serious…
READ MORE
By the time Paul Huling needed surgery last fall, he couldn’t use his left arm. Huling first noticed a problem a few weeks before when…
READ MORE
Soon-Shiong explained that N-803 had also proven effective in a first-in-human immunotherapy clinical trial combining an IL-15 superagonist with NantKwest’s off-the-shelf, PD-L1 tumor-targeted NK cells (NCT04050709) in…
READ MORE